PULM · Pulmatrix, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that, given the Company’s current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued without the closing of the Merger.”View the 10-Q filed May 15, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2023-01-26 | Cabell Christopher |
CMO & Head of R&D |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
1,700 |
| 2023-01-26 | Higgins Michael J |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
2,436 |
| 2023-01-26 | Raad Teofilo David |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
34,900 |
| 2023-01-26 | Varadan Anand |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
1,700 |
| 2023-01-26 | Siegert Michelle |
Vice President, Finance |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
9,900 |
| 2023-01-26 | Batycky Richard P. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
1,700 |
| 2023-01-26 | Wasilewski Margaret |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
11,400 |
| 2023-01-26 | Bazemore Todd |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
1,700 |
| 2022-04-18 | Ludlum Peter |
Interim CFO |
Other↑
|
No Securities Owned
|
0 |
| 2022-03-01 | Wasilewski Margaret |
Chief Medical Officer |
Other↑
|
No Securities Owned
|
0 |
| 2022-03-01 | Wasilewski Margaret |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest as follows: 25% of the options shall vest on the first anniversary of the grant date and 75% of the options shall vest in equal installments on the monthly anniversary date of each of the thirty-six (36) successive months after the first anniversary of the grant date, provided that the reporting person is providing services to the Issuer on the applicable vesting dates and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
21,060 |
| 2022-01-27 | Batycky Richard P. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
22,100 |
| 2022-01-27 | Bazemore Todd |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
22,100 |
| 2022-01-27 | Higgins Michael J |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
36,833 |
| 2022-01-27 | Raad Teofilo David |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
750,000 |
| 2022-01-27 | Varadan Anand |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
22,100 |
| 2022-01-27 | Cabell Christopher |
CMO & Head of R&D |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
22,100 |
| 2022-01-27 | Siegert Michelle |
Vice President, Finance |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
184,300 |
| 2021-07-26 | Varadan Anand |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2021-07-26 | Varadan Anand |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth (1/4) of the shares underlying this stock option will vest and become exercisable on the first anniversary of the date of grant, and an additional 2.083% of the shares underlying the options will vest on the last day of each of the thirty-six (36) months that follow the first anniversary of the date of grant, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
30,000 |
| 2021-01-28 | Higgins Michael J |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
25,000 |
| 2021-01-28 | Bazemore Todd |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
15,000 |
| 2021-01-28 | Batycky Richard P. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
15,000 |
| 2021-01-28 | Iwicki Mark T |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
15,000 |
| 2021-01-28 | Raad Teofilo David |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
565,500 |
| 2021-01-28 | Cabell Christopher |
CMO & Head of R&D |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
15,000 |
| 2021-01-28 | Munshi Amit |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
15,000 |
| 2021-01-28 | Siegert Michelle |
Vice President, Finance |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
91,900 |
| 2020-10-01 | Bazemore Todd |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2020-10-01 | Bazemore Todd |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth (1/4) of the shares underlying this stock option will vest and become exercisable on the first anniversary of the date of grant, and an additional 2.083% of the shares underlying this option will vest on the last day of each of the thirty-six (36) months that follow the first anniversary of the date of grant, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
30,000 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 5, 2018 and provided for 25% vesting on June 5, 2018 and the remaining 75% to vest in thirty-six (36) equal monthly installments with 2.083% for each of the next thirty-six (36) months that follow June 5, 2018. Vesting was accelerated for 2,581 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
12,400 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 9, 2020 and provided for vesting in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant. Vesting was accelerated for 12,813 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
15,000 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 16, 2019 and provided for vesting in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019. Vesting was accelerated for 10,313 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
15,000 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The securities and exercise prices shown have been adjusted from the time of grant to reflect the Issuer's 1-for-10 reverse stock split on February 3, 2019. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 5, 2018 and provided for 25% vesting on June 5, 2018 and the remaining 75% to vest in thirty-six (36) equal monthly installments with 2.083% for each of the next thirty-six (36) months that follow June 5, 2018. Vesting was accelerated for 2,581 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
12,400 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 2, 2020 and provided for vesting in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant. Vesting was accelerated for 9,167 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
10,000 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 24, 2015 and vested 100% on June 16, 2020. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
111 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 3, 2016 and vested 100% on February 3, 2020. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
880 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 9, 2020 and provided for vesting in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant. Vesting was accelerated for 12,813 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
15,000 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 16, 2019 and provided for vesting in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019. Vesting was accelerated for 10,313 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
15,000 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The securities and exercise prices shown have been adjusted from the time of grant to reflect the Issuer's 1-for-10 reverse stock split on February 3, 2019. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 3, 2016 and vested 100% on February 3, 2020. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
880 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The securities and exercise prices shown have been adjusted from the time of grant to reflect the Issuer's 1-for-10 reverse stock split on February 3, 2019. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 16, 2015 and vested 100% on June 16, 2020. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
1,771 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on March 20, 2017 and provided for 25% vesting on March 20, 2018 and the remaining 75% to vest in thirty-six (36) equal monthly installments with 2.083% for each of the next thirty-six (36) months that follow March 20, 2018. Vesting was accelerated for 63 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
440 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 2, 2020 and provided for vesting in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant. Vesting was accelerated for 9,167 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
10,000 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The securities and exercise prices shown have been adjusted from the time of grant to reflect the Issuer's 1-for-10 reverse stock split on February 3, 2019. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 24, 2015 and vested 100% on June 16, 2020. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
111 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 16, 2015 and vested 100% on June 16, 2020. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
1,771 |
| 2020-08-28 | GILLIS STEVEN |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The securities and exercise prices shown have been adjusted from the time of grant to reflect the Issuer's 1-for-10 reverse stock split on February 3, 2019. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on March 20, 2017 and provided for 25% vesting on March 20, 2018 and the remaining 75% to vest in thirty-six (36) equal monthly installments with 2.083% for each of the next thirty-six (36) months that follow March 20, 2018. Vesting was accelerated for 63 options that otherwise would not have become vested due to the reporting person's resignation. The post-termination exercise period was extended to September 1, 2021. |
Stock Option (Right to Buy)
|
440 |
| 2020-06-23 | Cabell Christopher |
CMO & Head of R&D |
Other↑
|
No Securities Owned
|
0 |
| 2020-06-23 | Cabell Christopher |
CMO & Head of R&D |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth (1/4) of the shares underlying this stock option will vest and become exercisable on the first anniversary of the date of grant, and an additional 2.083% of the shares underlying this option will vest on the last day of each of the thirty-six (36) months that follow the first anniversary of the date of grant, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
30,000 |
| 2020-04-21 | Higgins Michael J |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on May 21, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
15,000 |
| 2020-04-02 | GILLIS STEVEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on May 2, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Stock Option (Right to Buy)
|
10,000 |